S.Biomedics stated Friday it obtained the regulatory approval for part 1/2a scientific trials of the Parkinson’s illness cell remedy (A9-DPC), utilizing mind dopamine nerve precursor cells derived from human embryonic stem cells.
That is Asia’s first accredited scientific trial of a remedy for Parkinson’s illness utilizing dopamine cells derived from embryonic stem cells, the corporate stated.
Researchers within the U.S. and Europe are additionally competing to develop a similar-type Parkinson’s illness remedy.
The research will consider the security and efficacy of dopamine neural precursor cell transplantation remedy derived from homogeneous embryonic stem cells in sufferers who’ve been recognized with Parkinson’s illness for greater than 5 years. The trial will happen at Severance Hospital within the first half of this yr.
Parkinson’s illness is a degenerative mind illness during which 60-70 % of midbrain dopamine nerve cells die, leading to Parkinson’s disease-related motor signs.
Present remedy for Parkinson’s illness contains drug remedy akin to levodopa and deep mind stimulation, however the therapeutic impact decreases over time and numerous unwanted effects seem which this candidate remedy intends to beat.
S.BioMedics stated its cell remedy candidate demonstrated “wonderful” leads to behavioral exams utilizing a Parkinson’s illness monkey mannequin.
Signs of human-like Parkinson’s illness, akin to tremors, stiffness, and gradual movement, improved to a traditional degree after administration of dopamine neurotransmitters, the corporate stated. Exams utilizing PET-CT additionally confirmed that new dopamine neurons have been regenerated, it added.
“Greater than 20 years of analysis have resulted in scientific trial approval. Because it has proven wonderful results and security in preclinical research, we anticipate good leads to scientific trials so we may give hope to sufferers,” stated S.Biomedics CEO Kim Dong-wook.
Cho Myung-soo, head of analysis at S.Biomedics, added that the corporate is concurrently conducting part 1/2a scientific trials of embryonic stem cell-based spinal cord injury remedy and extreme ischemia remedy utilizing 3D cell aggregates and can purpose to beat different incurable illnesses.
Discussion about this post